File:Tool to assess glutamate in people with fragile X syndrome and other subtypes of autism spectrum disorder.pdf
Size of this JPG preview of this PDF file: 424 × 600 pixels. Other resolutions: 170 × 240 pixels | 339 × 480 pixels | 543 × 768 pixels | 1,239 × 1,752 pixels.
Original file (1,239 × 1,752 pixels, file size: 1.3 MB, MIME type: application/pdf, 16 pages)
File information
Structured data
Captions
Summary
editDescriptionTool to assess glutamate in people with fragile X syndrome and other subtypes of autism spectrum disorder.pdf |
English: This article provides guidelines to measure glutamatergic function in people with autism spectrum disorder and other neurodevelopmental disabilities to objectively assess the effects of potential beneficial interventions. |
Date | |
Source | see page 1 |
Author | see page 1/James Robert Brasic |
Licensing
editI, the copyright holder of this work, hereby publish it under the following license:
This file is licensed under the Creative Commons Attribution-Share Alike 4.0 International license.
- You are free:
- to share – to copy, distribute and transmit the work
- to remix – to adapt the work
- Under the following conditions:
- attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- share alike – If you remix, transform, or build upon the material, you must distribute your contributions under the same or compatible license as the original.
File history
Click on a date/time to view the file as it appeared at that time.
Date/Time | Thumbnail | Dimensions | User | Comment | |
---|---|---|---|---|---|
current | 22:23, 12 September 2021 | 1,239 × 1,752, 16 pages (1.3 MB) | Colassss (talk | contribs) | Uploaded own work with UploadWizard |
You cannot overwrite this file.
File usage on Commons
There are no pages that use this file.
Metadata
This file contains additional information such as Exif metadata which may have been added by the digital camera, scanner, or software program used to create or digitize it. If the file has been modified from its original state, some details such as the timestamp may not fully reflect those of the original file. The timestamp is only as accurate as the clock in the camera, and it may be completely wrong.
Short title | Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Idiopathic Autism Spectrum Disorder and Fragile X Syndrome: A Pilot Study |
---|---|
Image title | Multiple lines of evidence suggest that dysfunction of the metabotropic glutamate receptor subtype 5 (mGluR5) plays a role in the pathogenesis of autism spectrum disorder (ASD). Yet animal and human investigations of mGluR5 expression provide conflicting findings about the nature of dysregulation of cerebral mGluR5 pathways in subtypes of ASD. The demonstration of reduced mGluR5 expression throughout the living brains of men with fragile X syndrome (FXS), the most common known single-gene cause of ASD, provides a clue to examine mGluR5 expression in ASD. We aimed to (A) compare and contrast mGluR5 expression in idiopathic autism spectrum disorder (IASD), FXS, and typical development (TD) and (B) show the value of positron emission tomography (PET) for the application of precision medicine for the diagnosis and treatment of individuals with IASD, FXS, and related conditions. Two teams of investigators independently administered 3-[18F]fluoro-5-(2-pyridinylethynyl)benzonitrile ([18F]FPEB), a novel, specific mGluR5 PET ligand to quantitatively measure the density and the distribution of mGluR5s in the brain regions, to participants of both sexes with IASD and TD and men with FXS. In contrast to participants with TD, mGluR5 expression was significantly increased in the cortical regions of participants with IASD and significantly reduced in all regions of men with FXS. These results suggest the feasibility of this protocol as a valuable tool to measure mGluR5 expression in clinical trials of individuals with IASD and FXS and related conditions. |
Author | James Robert Brašić, Ayon Nandi, David S. Russell, Danna Jennings, Olivier Barret, Samuel D. Martin, Keith Slifer, Thomas Sedlak, John P. Seibyl, Dean F. Wong and Dejan B. Budimirovic |
Keywords |
|
Software used | LaTeX with hyperref |
Conversion program | pdfTeX-1.40.21 |
Encrypted | no |
Page size | 595.276 x 841.89 pts (A4) |
Version of PDF format | 1.7 |